India is often referred to as the ‘pharmacy of the world’ and is undeniably the leading manufacturing hub for many of the world’s most essential medicines.
Vulnerabilities or disruptions to the global medicine supply chain (including drug shortages) continue to make headlines.
Standards play an important role in the global medicines supply chain, helping governments and manufacturers increase the availability of safe, quality medicines, as well as building patient and health provider trust. In fact, quality standards are a big reason why we in the U.S. can get a prescription filled at our neighborhood pharmacy and trust that the medicine we receive will be safe and work as it should.
In this Q&A with the Duke-Margolis Drug Supply Chain Resilience and Advanced Manufacturing Consortium, US Pharmacopeia (USP) policy expert Amy B. Cadwallader highlights the importance of multi-disciplinary, cross-functional coordination to strengthen the medicine supply chain and global public health resilience in the face of ongoing threats, like persistent drug shortages. This Q&A was first published in the Consortium's eNewsletter and is re-printed with the permission of the Duke-Margolis Center for Health Policy.
The science of pharmaceutical continuous manufacturing (PCM) may not be entirely new but increasing interest in adoption of advanced manufacturing technologies (AMT) including PCM among industry and policymakers in recent years has been accompanied by strong support by FDA.
Advanced manufacturing technologies like pharmaceutical continuous manufacturing (PCM) can provide potential efficiencies for many medicines and their ingredients, thereby facilitating geographic diversity in manufacturing and supply chain resilience. One of the ways the U.S.